As of November 6, 2026, 7 holders' latest Schedule 13D or 13G filings report owning 5% or more of 4d Molecular Therapeutics, Inc. The largest reported stake is Janus Henderson Group Plc's, at 10.3%. 12 filings are on record since October 17, 2025 (Schedule 13G/A, April 7, 2026).
Sell to companies like 4d Molecular Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Bvf Partners L P · Percent: 9.99% · SCHEDULE 13G/A
- · Holder: RA Capital Management, L.P. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: State Street Corporation · Percent: 5.3% · SCHEDULE 13G
- · Holder: Janus Henderson Group Plc · Percent: 10.3% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
4d Molecular Therapeutics, Inc. has 12 Schedule 13D or 13G filings on record since 2025-10-17. 7 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Janus Henderson Group Plc | 10.3% | 5,247,151 | SCHEDULE 13G/A, 2026-04-07 | 2026-03-31 |
| Bvf Partners L P | 9.99% | 5,346,519 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| RA Capital Management, L.P. | 9.9% | 5,105,622 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Goldman Sachs Group, Inc. | 7.5% | 4,286,077 | SCHEDULE 13G/A, 2026-02-09 | 2025-12-31 |
| BlackRock, Inc. | 6.6% | 3,062,596 | SCHEDULE 13G/A, 2025-10-17 | 2025-09-30 |
| Novo Holdings A/S | 6.4% | 3,650,737 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| State Street Corporation | 5.3% | 2,707,875 | SCHEDULE 13G, 2026-05-12 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-26 | 2026-03-13 |
Holding shares or following this stake? See who's behind 4d Molecular Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on 4d Molecular Therapeutics, Inc. and the records around it.
4d Molecular Therapeutics, Inc. elsewhere on the record
- Leadership changes Mar 2026
- Who owns it
Companies that share a holder
- Novo Holdings A/S also filed stake reports on 11 other companies: Avalyn Pharma Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Obsidian Therapeutics, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch 4d Molecular Therapeutics, Inc.
Get an email when 4d Molecular Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on 4d Molecular Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on 4d Molecular Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on 4d Molecular Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-10-17 | BlackRock, Inc. | 6.6% | SCHEDULE 13G/A |
| 2025-10-20 | Novo Holdings A/S | 6.8% | SCHEDULE 13G |
| 2026-02-09 | The Goldman Sachs Group, Inc. | 7.5% | SCHEDULE 13G/A |
| 2026-02-17 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-02-17 | Janus Henderson Group Plc | 8.1% | SCHEDULE 13G |
| 2026-02-17 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
| 2026-02-17 | Novo Holdings A/S | 6.4% | SCHEDULE 13G/A |
| 2026-03-26 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-07 | Janus Henderson Group Plc | 10.3% | SCHEDULE 13G/A |
| 2026-05-12 | State Street Corporation | 5.3% | SCHEDULE 13G |
| 2026-05-15 | Bvf Partners L P | 9.99% | SCHEDULE 13G/A |
| 2026-05-15 | RA Capital Management, L.P. | 9.9% | SCHEDULE 13G/A |
Questions about who owns 4d Molecular Therapeutics, Inc.
Who owns 4d Molecular Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of 4d Molecular Therapeutics, Inc.: Janus Henderson Group Plc (10.3%, Schedule 13G/A, filed 2026-04-07), Bvf Partners L P (9.99%, Schedule 13G/A, filed 2026-05-15), RA Capital Management, L.P. (9.9%, Schedule 13G/A, filed 2026-05-15), The Goldman Sachs Group, Inc. (7.5%, Schedule 13G/A, filed 2026-02-09) and BlackRock, Inc. (6.6%, Schedule 13G/A, filed 2025-10-17); 2 more are listed above.
Who are the largest shareholders of 4d Molecular Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of 4d Molecular Therapeutics, Inc. on this page are Janus Henderson Group Plc (10.3%), Bvf Partners L P (9.99%) and RA Capital Management, L.P. (9.9%).
When did Janus Henderson Group Plc buy into 4d Molecular Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Janus Henderson Group Plc on this page is the Schedule 13G, filed 2026-02-17, reporting 8.1%; its latest, Schedule 13G/A filed 2026-04-07, reports 10.3%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for 4d Molecular Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| March 30, 2026 | Leadership change: Kristian Humer appointed, Principal Accounting Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for 4d Molecular Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.